BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34068008)

  • 1. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.
    Gupta N; Gaikwad S; Kaushik I; Wright SE; Markiewski MM; Srivastava SK
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
    Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
    Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.
    Gupta N; Srivastava SK
    Mol Cancer Ther; 2019 Oct; 18(10):1708-1720. PubMed ID: 31270151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494.
    Moaaz M; Lotfy H; Elsherbini B; Motawea MA; Fadali G
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3393-3403. PubMed ID: 33247701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
    Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
    Sangaletti S; Tripodo C; Santangelo A; Castioni N; Portararo P; Gulino A; Botti L; Parenza M; Cappetti B; Orlandi R; Tagliabue E; Chiodoni C; Colombo MP
    Cell Rep; 2016 Sep; 17(1):233-248. PubMed ID: 27681434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
    Zonneville J; Colligan S; Grant S; Miller A; Wallace P; Abrams SI; Bakin AV
    Int J Cancer; 2020 Oct; 147(8):2279-2292. PubMed ID: 32452014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
    Ranjan A; Wright S; Srivastava SK
    Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.
    Markiewski MM; Vadrevu SK; Sharma SK; Chintala NK; Ghouse S; Cho JH; Fairlie DP; Paterson Y; Astrinidis A; Karbowniczek M
    J Immunol; 2017 Apr; 198(7):2989-2999. PubMed ID: 28228558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo.
    Cao Y; Feng YH; Gao LW; Li XY; Jin QX; Wang YY; Xu YY; Jin F; Lu SL; Wei MJ
    Int Immunopharmacol; 2019 May; 70():110-116. PubMed ID: 30798159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 suppresses tumor growth in breast cancer-bearing mice by negatively regulating myeloid-derived suppressor cell functions.
    Hong HJ; Lim HX; Song JH; Lee A; Kim E; Cho D; Cohen EP; Kim TS
    Cancer Immunol Immunother; 2016 Jan; 65(1):61-72. PubMed ID: 26613952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
    Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
    Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach.
    Juin SK; Ghosh S; Majumdar S
    Int Immunopharmacol; 2020 Nov; 88():106932. PubMed ID: 32890791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.
    Franklin DA; Sharick JT; Ericsson-Gonzalez PI; Sanchez V; Dean PT; Opalenik SR; Cairo S; Judde JG; Lewis MT; Chang JC; Sanders ME; Cook RS; Skala MC; Bordeaux J; Orozco Bender J; Vaupel C; Geiss G; Hinerfeld D; Balko JM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quercetin exerts anti-tumor immune mechanism by regulating IL-6/JAK2/STAT3 signaling pathway to deplete Treg cells.
    Liao Y; Xie X; Zhang C; Zhong H; Shan L; Yu P; Xu L
    Toxicon; 2024 May; 243():107747. PubMed ID: 38714236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
    Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
    Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
    Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.